Optimization of artificial intelligence models for prediction of new-onset cardiovascular disease in patients with arterial hypertension

Enrique Rodilla, Olast Arrizibita-Iriarte, Blanca Miranda-Serrano, Luis-Miguel Ruilope-Urioste, Germán Sedano-Gil, Alberto Ortiz, José-Antonio Costa-Muñoz, José Chordá-Ribelles, Maialen Zabalza-Zudaire and Onintza Sayar-Beristain

PLOS Digital Health, 2026, vol. 5, issue 5, 1-18

Abstract: Advanced preventive strategies are needed to decrease the burden of cardiovascular disease (CVD). We aimed to develop a predictive tool to identify individuals at higher CVD risk and facilitate proactive interventions to improve clinical outcomes. This single-center retrospective study enrolled consecutive hypertensive subjects free of CVD at baseline and followed them up for a mean of 8.3 years. The primary outcome was new-onset CVD (ischemic heart disease, stroke or hospitalization due to heart failure). The 155-variable dataset was enriched by creating trend variables using statistical measures, Principal Component Analysis (PCA) and Latent Class Analysis (LCA). Then, an artificial intelligence (AI) XGBoost prediction algorithm was trained on 70% of the dataset and validated on the remaining 30%. XGBoost-based risk stratification was compared with risk stratification according to SCORE2. The 3,588 consecutive patients enrolled had a mean age of 54.2 ± 14 years, 53% were women. The incidence rate of new-onset CVD was 1.93 (95% CI: 1.78-2.09) per 100 patient-years. The XGBoost model incorporated 30 variables and achieved 86% ROC AUC, 81% sensitivity, and 78% specificity for predicting CVD. The number of antihypertensive drugs had the strongest predictive power within the model. SCORE2 classified at baseline only 32% of participants with a CV event in the follow-up as high or very-high risk, whereas the XGBoost model correctly identified 81% of them. AI-based modeling outperformed SCORE2 in predicting new-onset CVD in patients with hypertension, identifying the number of antihypertensive drugs as a key predictor and supporting the role of AI risk stratification in clinical practice to implement precision medicine.Author summary: Cardiovascular disease (CVD) remains a leading cause of illness and death, highlighting the need for better ways to identify people at high risk before problems occur. In this study, we developed and tested an artificial intelligence (AI) tool to improve prediction of new-onset CVD in people with high blood pressure but no prior cardiovascular disease.

Date: 2026
References: Add references at CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/digitalhealth/article?id=10.1371/journal.pdig.0001441 (text/html)
https://journals.plos.org/digitalhealth/article/fi ... 01441&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pdig00:0001441

DOI: 10.1371/journal.pdig.0001441

Access Statistics for this article

More articles in PLOS Digital Health from Public Library of Science
Bibliographic data for series maintained by digitalhealth ().